Sorry, bio. It was meant to be tongue-in-cheek. But honestly, I don't think the trials were large enough to draw the conclusions that you want to draw, although your point is well-taken and your conclusion may well be correct. What I want to see is the unbundled data from the 208 trial and, of course, data from the 209.
I think Jason Kantor has got it right: The 10mg and 20mg are sub-optimal dosing levels. I'm thinking the unbundled data from the 208 will support that conclusion and, hence, give GENR some good info for designing the Phase III's and, just as importantly, help in working out the protocols for the SPA.
Maybe the optimal dose is somewhere between 40mg and 70mg, but it certainly seems not to be under 40mg. Personally, I think it was unwise for Levitt to present the unbundled results in a public forum, when he knew damn well that the results would be perceived as less than stellar. He could have waited, saying that the company needed more time to analyze the data. I'm sure the conspiratorialists on the Yahoo board will find some nefarious reason for his--what I consider--blunder. Hey, if you still believe in the story and you've got available funds, then thank Levitt for the buying opportunity. I know some are predicting a $1.25 soon, but I don't think so. I think it moves up from here. Geez, the results weren't bad; they just weren't that great.
Bladerunner
Market Data 
Markets 
AI
